Thwarting Recurrence in Young Breast Ca Patients

December 11, 2014 10:13 PM

1 0

SAN ANTONIO -- Disease-free survival (DFS) did not improve significantly among premenopausal breast cancer patients treated with tamoxifen and ovarian suppression, except for patients who remained premenopausal after chemotherapy, an international randomized trial showed.

After a median follow-up of 5.6 years, patients treated with tamoxifen alone had a DFS of 84.7% compared with 86.6% with the addition of ovarian suppression. Patients who retained ovarian function had a statistically significant 22% reduction in the DFS hazard with the addition of ovarian suppressio...

Read more

To category page